Antibacterial activity of novel bacterial topoisomerase inhibitors against key veterinary pathogens

  • Vet Microbiol. 2023 Jul 29;284:109840. doi: 10.1016/j.vetmic.2023.109840.
Hilary A Phelps  1 ,  Michael Kuhn  1 ,  Yanran Lu  2 ,  Sandip Vibhute  2 ,  Jeffrey L Watts  1 ,  Mark J Mitton-Fry  3
Affiliations
  • 1. Global Therapeutics, Anti-Infectives Research, Zoetis, 333 Portage Street, Kalamazoo, MI 49007, United States.
  • 2. Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, 500 West 12th Avenue, Columbus, OH 43210, United States.
  • 3. Division of Medicinal Chemistry and Pharmacognosy, College of Pharmacy, The Ohio State University, 500 West 12th Avenue, Columbus, OH 43210, United States. Electronic address: [email protected].
PMID: 37531840 DOI: 10.1016/j.vetmic.2023.109840
Abstract

Multidrug-resistant bacteria infect companion Animals and livestock in addition to their devastating impact on human health. Novel Bacterial Topoisomerase Inhibitors (NBTIs) with excellent activity against Gram-positive bacteria have previously been identified as promising new Antibacterial agents. Herein, we evaluate the Antibacterial activity of these NBTIs against a variety of important veterinary pathogens and demonstrate outstanding in vitro activity, especially against staphylococci.

Keywords
Antagonists & Inhibitors; Mastitis; Staphylococcus.
Products